Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Avadel Pharmaceuticals PLC / Equity Bottom-Up

<ul><li>Avadel Pharmaceuticals is suddenly at the center of a high-stakes bidding war, with strategic interest intensifying as its once-nightly sleep therapy, LUMRYZ, continues to scale commercially.</li><li>On November 14, Danish drugmaker Lundbeck submitted an unsolicited offer to acquire Avadel for up to $23 per share—topping an earlier $20-per-share bid from Alkermes made in October.</li><li>The structure of Lundbeck’s offer includes $21.00 in cash and a $2.00 per share non-transferable contingent value right (CVR) tied to future sales milestones for LUMRYZ and valiloxybate.</li></ul>

Avadel Pharmaceuticals is suddenly at the center of a high-stakes bidding war, with strategic interest intensifying as its once-nightly sleep therapy, LUMRYZ, continues to scale commercially.On November 14, Danish drugmaker Lundbeck submitted an unsolicited offer to acquire Avadel for up to $23 per share—topping an earlier $20-per-share bid from Alkermes made in October.The structure of Lundbeck’s offer includes $21.00 in cash and a $2.00 per share non-transferable contingent value right (CVR) tied to future sales milestones for LUMRYZ and valiloxybate.

Avadel Sparks Bidding War: Why Lundbeck’s Offer Is Shaking Things Up!

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Key points (machine generated)<ul><li>AVDL is a pharmaceutical company that has recently launched LUMRYZ, a drug used to treat Narcolepsy, a rare sleeping disorder.</li><li>LUMRYZ is an improved version of two existing drugs, Xyrem and Xywav, which generate $1.9 billion in annual revenue and have around 16,000 patients on the drug.</li><li>LUMRYZ aims to address the inconvenience of the unusual dosing profile of Xyrem and Xywav, which require patients to take two doses, with the second dose taken in the middle of the night.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)AVDL is a pharmaceutical company that has recently launched LUMRYZ, a drug used to treat Narcolepsy, a rare sleeping disorder.LUMRYZ is an improved version of two existing drugs, Xyrem and Xywav, which generate $1.9 billion in annual revenue and have around 16,000 patients on the drug.LUMRYZ aims to address the inconvenience of the unusual dosing profile of Xyrem and Xywav, which require patients to take two doses, with the second dose taken in the middle of the night.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Avadel Pharmaceuticals -Adr (AVDL) - Monday, Oct 30, 2023

United States

Avadel Pharmaceuticals Public Limited Company operates as specialty pharmaceutical company. The Company develops a medicines for chronic urological, central nervous system, and sleep disorders. Avadel Pharmaceuticals serves hospitals worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avadel Pharmaceuticals PLC (AVDL US)

Avadel Sparks Bidding War: Why Lundbeck’s Offer Is Shaking Things Up!

Avadel Pharmaceuticals is suddenly at the center of a high-stakes bidding war, with strategic interest intensifying as its once-nightly sleep...

Baptista Research

Avadel Pharmaceuticals -Adr (AVDL) - Monday, Oct 30, 2023

Key points (machine generated) AVDL is a pharmaceutical company that has recently launched LUMRYZ, a drug used to treat Narcolepsy, a rare...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)